Treatment of Schizophrenia and Comorbid Substance Abuse: Pharmacologic Approaches

Alan I. Green, M.D.

Co-occurring substance use disorder is common among patients with schizophrenia, and its presence greatly worsens the course of schizophrenia. A number of theories have been introduced to explain the increased rate of substance use disorder in these patients. These theories include the notion that substance use could trigger psychotic symptoms in vulnerable individuals and the idea that the substances are used to self-medicate symptoms of schizophrenia. Our group and others have advanced a neurobiological hypothesis to explain this comorbidity—that a mesocorticolimbic brain reward circuit underlies the substance use disorder in patients with schizophrenia. Treatment of substance use disorder in these patients is best done with integrated treatment programs that combine psychosocial interventions with pharmacotherapy. Recent data suggest that the atypical antipsychotic clozapine and perhaps other atypical agents may lessen substance use in patients with schizophrenia. My colleagues and I have hypothesized that clozapine’s effect in these patients may be related to its ability to decrease the brain reward circuit dysfunction. Research is continuing on the use of atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. The adjunctive use of naltrexone or other agents also may be helpful. Further research on the optimal pharmacologic approach to patients with dual diagnosis is needed.

OVERVIEW OF DUAL DIAGNOSIS

Substance use disorder—the abuse of or dependence on substances—is common among patients diagnosed with schizophrenia. The primary substances of abuse include alcohol (the most common), cannabis, and cocaine.1–7 According to the Epidemiologic Catchment Area (ECA) study,8 the lifetime prevalence of substance use disorder (e.g., with alcohol or other substances) in patients with schizophrenia is 47%, a rate approximately 3 times the background rate in the general population. Alcohol use disorder itself is found in 34% (3 times the rate of the general population), and any other substance use disorder occurs in 28% of these patients (6 times the rate of the general population). In addition, nicotine use is also very common. Studies suggest that 75% to 90% of patients with schizophrenia smoke tobacco, as compared with approximately 21% of the general population.9

The high rate of substance use disorder is not found only in patients with chronic schizophrenia; a number of studies have indicated that it is very common in patients early in the course of the disorder.10–12 For example, a recent study11 of pharmacologic treatment for patients in their first episode of schizophrenia, which specifically excluded patients in whom recent substance use could have confused the actual diagnosis of schizophrenia, found that 37% of 262 first-episode patients (recruited from sites throughout North America and Europe) had a history of substance use disorder. In this study,11 28% of the patients had a lifetime...
diagnosis of cannabis use disorder, and 21% had a lifetime diagnosis of alcohol use disorder. For more information on the presence of this comorbidity, please refer to Buckley in this supplement.

**COMPLICATIONS OF COMORBID SUBSTANCE USE DISORDERS**

According to a study by Hambrecht and Hafner, patients with schizophrenia and comorbid substance use disorders tended to have an earlier age at onset of schizophrenia than patients who did not use substances (the age at onset was 17.7 years of age versus 25.7 years of age, respectively). In another study of first-episode schizophrenia, a history of cannabis use disorder was associated with an earlier age at onset of schizophrenia (by approximately 2 years). Moreover, in this study, the patients with a history of cannabis use disorder had a poorer response to acute treatment than patients without a history of cannabis use disorder.

Studies of patients with chronic schizophrenia have also clearly indicated that co-occurring substance use disorder is associated with poorer overall outcome. These dual-diagnosis patients have higher relapse rates, more treatment noncompliance, poorer overall response to pharmacotherapy, higher hospitalization rates, increased risk for violence, and higher medical costs than those patients with schizophrenia who do not use substances. For example, Buchanan et al. noted that patients with negative symptoms are actually less likely to use substances than other patients with schizophrenia.

Our group has published a neurobiological formulation suggesting that the dysregulated dopamine-mediated mesocorticolimbic network in patients with schizophrenia may underlie their substance abuse. This theory, based on animal research, suggests that this dysregulated network, which subsumes brain reward circuitry, is partially ameliorated by substances of abuse, even while the substance use worsens the overall course of patients with schizophrenia. Thus, according to this formulation, use of substances may transiently allow patients with schizophrenia to experience normal rewards from daily life. Chambers et al. have also published a neurobiological theory consistent with our formulation.

**TREATMENT OF DUAL DIAGNOSIS**

Although pharmacologic interventions are focused upon in this section, psychosocial interventions are necessary as well to provide complete and effective treatment to dual-diagnosis patients. In integrated dual-diagnosis treatment programs, one treatment team can deliver medication management as well as substance abuse and psychosocial treatment services.

**Antipsychotics**

Classical or typical antipsychotics, first introduced in the 1950s, are potent dopamine-2 (D2) receptor blockers. Although these agents have been shown to be useful for the treatment of patients with schizophrenia, their beneficial effects are somewhat limited. Some patients do not respond to these antipsychotics, others cannot readily tolerate them because of side effects, and many patients who respond acutely may lose their response over time. In addition, cognitive deficits and negative symptoms, important parts of the symptom profile of schizophrenia, are not generally ameliorated by these agents. Last, these medications do not appear to decrease substance abuse in patients with schizophrenia, and there is some suggestion that use of these
medications may even make substance abuse more likely.4,5,29,33 For example, McEvoy et al.33 demonstrated that the use of haloperidol increased the rate of smoking in patients with schizophrenia. Overall, the typical antipsychotic medications appear to be of limited value for controlling substance use or substance abuse in patients with schizophrenia.

There has been hope that the novel or atypical antipsychotic medications may be of greater value than typical antipsychotics in patients with schizophrenia and co-occurring substance use disorders. Although there is considerable controversy about whether the novel antipsychotics are more efficacious than the typical agents,1,3,5 the lack of extrapyramidal side effects, the possibility that they are associated with fewer relapses,36 the possible improvement in some cognitive deficits,37 and the overall tolerability of these agents have led them to become first line treatments for many patients with schizophrenia.

Of the atypical antipsychotics, clozapine stands out as being the most valuable medication in the treatment of patients with schizophrenia and co-occurring substance use disorders. It is generally considered the most efficacious antipsychotic treatment agent for patients with schizophrenia.38 Clozapine has been associated with decreased cocaine craving,39 decreased smoking rates,40,41 decreased psychosis,39,42,43 decreased substance use,42–46 and increased rates of abstinence in these patients.39,42,45,46 One study39 of 29 treatment-refractory patients with dual diagnosis indicated that clozapine reduced psychopathology and improved psychosocial functioning, and semi-structured interviews indicated a decrease in substance use. Drake et al.44 conducted a naturalistic, longitudinal study of 151 dual-diagnosis, treatment-refractory patients, and the results showed a 79% remission rate of alcohol abuse and a 63% remission rate of drug abuse in patients treated with clozapine (Figure 1). Additionally, a retrospective survey46 of 36 patients with schizophrenia and active substance use disorder demonstrated that 85% of patients experienced a decrease in substance use and 72% of patients achieved abstinence during treatment. Although case reports and nonprospective studies have suggested clozapine is an efficacious agent, prospective randomized trials are currently being conducted to fully assess the effects of this atypical antipsychotic in dual-diagnosis patients.

My colleagues and I31 have proposed that although clozapine, like other atypical antipsychotic medications, appears to increase dopamine release in the prefrontal cortex, the unique effects of clozapine in patients with schizophrenia and co-occurring substance use disorders relate to its broad profile of pharmacologic effects. Specifically, clozapine produces weak D2 receptor blockade, potent noradrenergic α1 receptor blockade, and a profound release of norepinephrine, which together may be able to improve the signal-detection capacity of the mesocorticolimbic dopamine-mediated circuitry. In essence, then, we have suggested that clozapine may be able to correct (or normalize) the mesocorticolimbic brain reward circuit deficiency that underlies substance abuse in these patients.31,47

Other atypical antipsychotics include risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. A number of these agents have been studied in patients with dual diagnosis, but there is less information about the effects of these medications than there is for clozapine. In one study,48 risperidone treatment was associated with decreased cue-related craving, decreased negative and global symptoms, and decreased substance abuse relapses in patients with schizophrenia and comorbid cocaine dependence. However, in a retrospective study49 of 41 dual-diagnosis patients, abstinence rates (for alcohol and/or cannabis) were substantially higher (54%) in patients treated with clozapine than in patients treated with risperidone (13%).

Olanzapine has been demonstrated to be as efficacious for the treatment of psychosis in patients with schizophrenia and comorbid substance use disorders as it is in patients with only schizophrenia.50 However, although Noordsy et al.51 found that patients who switched treatment to olanzapine from typical antipsychotics experienced improvements in their alcohol and drug use as compared with their baseline usage, the same level of improvement was noted in those individuals who remained on typical antipsychotics. Other studies52,53 have shown that olanzapine may reduce cravings for and use of cocaine in patients with schizophrenia. Last, Littrell et al.54 reported that olanzapine decreased substance use in 70% of those treated (N = 30). These studies suggest that although olanzapine may have beneficial effects in the dual-diagnosis population, further work is needed to fully understand the extent of those effects.

Among the other atypical agents, quetiapine has been associated with improvement in psychiatric symptoms and with a reduction of stimulant cravings in patients with psychiatric illnesses who switched from typical antipsychotic treatment to quetiapine.55 Moreover, studies56,57 of aripiprazole, another atypical antipsychotic, reported that patients treated with this agent had decreased craving for alcohol or...
cocaine, decreased use of alcohol or cocaine, and a decreased number of positive drug screens.

**Adjunctive Agents**

Other agents have been used adjunctively with antipsychotic pharmacotherapy in attempts to treat patients with schizophrenia and substance use disorder, most specifically for co-occurring alcohol use disorder. Although a number of medications have been developed for use in alcohol use disorder, only a few of them have been tried in patients with schizophrenia. Disulfiram has shown some beneficial effects in this population, although there has been some concern about the possibility of an increase in psychosis in patients with schizophrenia taking this agent. Thus, caution is usually advised when using disulfiram with these patients. Naltrexone, an opioid antagonist, has been approved for use in the treatment of alcoholism.

In addition, topiramate, a medication approved for the treatment of alcohol use disorder, only a few of them have been tried in patients with schizophrenia. Disulfiram has shown some beneficial effects in this population, although there has been some concern about the possibility of an increase in psychosis in patients with schizophrenia taking this agent. Thus, caution is usually advised when using disulfiram with these patients. Naltrexone, an opioid antagonist, has been approved for use in the treatment of alcoholism.

**Drug names:** acamprosate (Campral), aripiprazole (Abilify), clozapine (FazaClo ODT, Clozaril, and others), desipramine (Norpramin and others), disulfiram (Antabuse), haloperidol (Haldol and others), naltrexone (Revia, Vivitrol, and others), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), topiramate (Topamax), ziprasidone (Geodon).

**Disclosure of off-label usage:** The author has determined that, to the best of his knowledge, clozapine, desipramine, olanzapine, quetiapine, and ziprasidone are not approved by the U.S. Food and Drug Administration for the treatment of comorbid substance use disorder and topiramate is not approved for the treatment of alcoholism.

**REFERENCES**

17. Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and may be able to decrease substance use in this population. Adjunctive medications, some of which have been recently approved for the treatment of alcohol use disorder, may be helpful in these patients, although research on these agents is in an even more preliminary state than that on the role of atypical antipsychotic agents in this population. Whatever the pharmacologic treatment intervention, however, these dual-diagnosis patients appear to do best in an integrated dual-diagnosis program, in which psychosocial approaches and medication management are delivered by one team specifically trained for this purpose.

**CONCLUSION**

Substance use disorder in patients with schizophrenia can lead to an exacerbation of the psychosis and a poor long-term outcome. Pharmacologic interventions that can limit the substance use, in both chronic patients as well as in those in the early phases of schizophrenia, are important to develop. Typical antipsychotics appear to be of limited value in controlling the substance abuse in patients with schizophrenia, whereas preliminary studies suggest that some of the atypical antipsychotics, especially clozapine,


24. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201–225.


35. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:81–85.


